US › Healthcare

Lexicon Pharmaceuticals Inc (LXRX)

US · Healthcare · Biotechnology

$2.49+6.87%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$21.1M
Revenue YoY
+1572.1%
Net profit
$-1.0M
Profit YoY
+95.9%
EPS
$-0.00
EPS estimate
$-0.04
Net margin
-4.9%

EPS came in at -0.00 against a street estimate of -0.04 — a beat of 93.5%.

Key statistics

Market cap
$1.03B
Forward P/E
0.0
P/B
5.06
Book value
$0.48
EPS (TTM)
$-0.07
52-week high
$2.68
52-week low
$1.02
50-day MA
$2.18
200-day MA
$1.67
Beta
1.05

Analyst view

Analysts rate Lexicon Pharmaceuticals Inc a buy (3 buy, 2 hold, 0 sell out of 5) with an average price target of $3.77.

Shareholding

Insiders
1.12%
Institutions
78.59%

Largest institutional holders

FundStake
Artal Group S A34.83%
FMR Inc10.14%
Siren, L.L.C.9.97%
Sessa Capital, L.P4.03%
Vanguard Capital Management, LLC2.14%
Point72 Asset Management, L.P.1.76%
Millennium Management LLC1.11%
BlackRock Inc0.75%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Lexicon Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.